ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$4.25 USD
+0.09 (2.16%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.26 +0.01 (0.24%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for ImmunityBio, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -583.85 | -417.32 | -349.85 | -92.38 | -65.79 |
Depreciation/Amortization & Depletion | 60.77 | 35.86 | 14.24 | 9.94 | 9.01 |
Net Change from Assets/Liabilities | 3.98 | -8.00 | -19.11 | 5.25 | -10.94 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 152.35 | 51.95 | 80.30 | 6.74 | 6.35 |
Net Cash From Operating Activities | -366.76 | -337.51 | -274.42 | -70.45 | -61.36 |
Property & Equipment | -30.58 | -78.16 | -13.07 | -2.64 | -4.18 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.11 | 126.69 | -71.82 | -17.95 | 25.64 |
Other Investing Activities | 0.00 | -21.23 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -30.47 | 27.30 | -84.89 | -20.59 | 21.46 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 110.40 | 0.07 | 169.99 | 87.48 | 38.72 |
Issuance (Repayment) of Debt | 258.62 | 234.49 | 338.50 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 189.32 | -0.96 | -3.05 | -0.50 | -0.13 |
Net Cash from Financing Activities | 558.34 | 233.61 | 505.44 | 86.98 | 38.59 |
Effect of Exchange Rate Changes | -0.29 | 0.28 | 0.05 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 160.82 | -76.32 | 146.19 | -4.07 | -1.31 |
Cash at Beginning of Period | 104.97 | 181.28 | 35.09 | 15.69 | 17.00 |
Cash at End of Period | 265.79 | 104.97 | 181.28 | 11.62 | 15.69 |
Diluted Net EPS | -1.15 | -1.04 | -0.89 | -0.89 | -0.70 |
Fiscal Year End for ImmunityBio, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -268.71 | -134.13 | -583.85 | -350.44 | -254.80 |
Depreciation/Amortization & Depletion | 20.34 | 9.61 | 60.77 | 49.21 | 33.19 |
Net Change from Assets/Liabilities | 1.47 | -3.89 | 3.98 | 29.73 | 36.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 39.57 | 21.43 | 152.35 | 20.02 | 20.80 |
Net Cash From Operating Activities | -207.33 | -106.98 | -366.76 | -251.49 | -164.08 |
Property & Equipment | -1.99 | -1.26 | -30.58 | -22.63 | -16.95 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -85.13 | -34.36 | 0.11 | -10.09 | -0.13 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -87.11 | -35.62 | -30.47 | -32.72 | -17.09 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 66.57 | 14.12 | 110.40 | 101.04 | 13.88 |
Issuance (Repayment) of Debt | -0.04 | -0.02 | 258.62 | 258.64 | 106.84 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 92.59 | -3.87 | 189.32 | -1.88 | -0.42 |
Net Cash from Financing Activities | 159.12 | 10.23 | 558.34 | 357.80 | 120.30 |
Effect of Exchange Rate Changes | -0.03 | -0.04 | -0.29 | -0.27 | -0.26 |
Net Change In Cash & Equivalents | -135.35 | -132.42 | 160.82 | 73.33 | -61.14 |
Cash at Beginning of Period | 265.79 | 265.79 | 104.97 | 104.97 | 104.97 |
Cash at End of Period | 130.44 | 133.37 | 265.79 | 178.30 | 43.83 |
Diluted Net EPS | -0.20 | -0.20 | -0.37 | -0.19 | -0.32 |